Drug recall · September 19, 2018
Argatroban Injection recall
Why: Failed Impurities/Degradation Specifications; Out of specification stability testing results at the 18 month time point
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Argatroban Injection, 250 mg/2.5 mL (100 mg/mL), 2.5 mL Single-use Vial, Rx only, Sterile, Manufactured for: Hospira, Inc, Lake Forest, IL 60045 USA. NDC: 0409-1140-01
- Lots / codes
Lot: DP602, 10/2018
- Quantity
- 1,580 vials
- Company
- Pfizer Inc., New York, NY
- Distribution
- Nationwide USA
- Initiated
- August 28, 2018 · Voluntary: Firm initiated
- Classified
- September 7, 2018
- Reported
- September 19, 2018
- Ended
- June 26, 2020
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Argatroban
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.